Skip to main content
. 2022 Sep 19;2022:2322417. doi: 10.1155/2022/2322417

Table 2.

25 potential therapeutic targets of TFDC for GA.

No. Target Symbol Entrez ID
1 72 kDa type IV collagenase MMP2 4,313
2 Plasminogen activator inhibitor 1 SERPINE1 5,054
3 Mitogen-activated protein kinase 14 MAPK14 1,432
4 Urokinase-type plasminogen activator PLAU 5,328
5 ATP-binding cassette sub-family G member 2 ABCG2 9,429
6 Heme oxygenase 1 HMOX1 3,162
7 Nitric oxide synthase, inducible NOS2 4,843
8 Stromelysin-1 MMP3 4,314
9 Cytosolic phospholipase A2 PLA2G4A 5,321
10 Mitogen-activated protein kinase 1 MAPK1 5,594
11 Prostaglandin G/H synthase 2 PTGS2 5,743
12 C-X-C motif chemokine 2 CXCL2 2,920
13 Interleukin-1 beta IL1B 3,553
14 Amine oxidase [flavin-containing] A MAOA 4,128
15 Prostaglandin G/H synthase 1 PTGS1 5,742
16 5-Hydroxytryptamine receptor 3A HTR3A 3,359
17 Peroxisome proliferator activated receptor gamma PPARG 5,468
18 C-reactive protein CRP 1,401
19 C–C motif chemokine 2 CCL2 6,347
20 Transcription factor p65 RELA 5,970
21 Interleukin-6 IL6 3,569
22 Sodium-dependent dopamine transporter SLC6A3 6,531
23 Nuclear factor erythroid 2-related factor 2 NFE2L2 4,780
24 Matrix metalloproteinase-9 MMP9 4,318
25 Monocyte differentiation antigen CD14 CD14 929